The U.S. Food and Drug Administration (FDA) approved three medications this summer that represent medical breakthroughs in the treatment of heart disease and sexual desire. Alirocumab and evolocumab are the first in an entirely new class of injectable cholesterol lowering medications known as PCSK9 inhibitors while flibanserin—also known as “Addyi”—is the first FDA approved treatment
READ MORE ARTICLES